This guideline is the basis of QS129.
Ov Overview erview
This guideline covers long-acting reversible contraception. It aims to increase the use of long-action reversible contraception by improving the information given to women about their contraceptive choices.
In March 2019 we revised our decision on how to implement the recommendations of our October 2017 review. Although no new evidence was identified, we noted significant changes in how we commission and provide contraceptive services in England. We have removed the recommendations in this guideline that no longer fit with current practice. There are also many new LARC products now available. See our long-acting reversible contraception: implementation resource summary for links to the latest information.
Who is it for?

Introduction Introduction
It is estimated that about 30% of pregnancies are unplanned. The effectiveness of the barrier method and oral contraceptive pills depends on their correct and consistent use. By contrast, the effectiveness of long-acting reversible contraceptive (LARC) methods does not depend on daily concordance. The uptake of LARC is low in Great Britain, at around 12% of women aged 16-49 in 2008-09, compared with 25% for the oral contraceptive pill and 25% for male condoms.
Expert clinical opinion is that LARC methods may have a wider role in contraception and their increased uptake could help to reduce unintended pregnancy. The current limited use of LARC suggests that healthcare professionals need better guidance and training so that they can help women make an informed choice. Health providers and commissioners also need a clear understanding of the relative cost effectiveness of LARC compared with other methods of fertility control. Enabling women to make an informed choice about LARC and addressing women's preferences is an important objective of this guideline.
LARC is defined in this guideline as contraceptive methods that require administration less than once per cycle or month. Included in the category of LARC are:
copper intrauterine devices progestogen-only intrauterine systems progestogen-only injectable contraceptives progestogen-only subdermal implants
The guideline offers the best-practice advice for all women of reproductive age who may wish to regulate their fertility by using LARC methods. It covers specific issues for the use of these methods during the menarche and before the menopause, and by particular groups, including women who have HIV, learning disabilities or physical disabilities, or are younger than 16 years.
Drug recommendations
The guideline will assume that prescribers will use a drug's summary of product characteristics to inform decisions made with individual patients. NICE has produced guidance on the components of good patient experience in adult NHS services.
All healthcare professionals should follow the recommendations in patient experience in adult NHS services.
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1.1.5.2 Women with learning and/or physical disabilities should be supported in making their own decisions about contraception.
1.1.5.3 Contraception should be seen in terms of the needs of the individual rather than in terms of relieving the anxieties of carers or relatives.
1.1.5.4 When a woman with a learning disability is unable to understand and take responsibility for decisions about contraception, carers and other involved parties should meet to address issues around the woman's contraceptive need and to establish a care plan.
1.1.6 1.1.6 T Tr raining of healthcare professionals in contr aining of healthcare professionals in contraceptiv aceptive care e care
1.1.6.1 Healthcare professionals advising women about contraceptive choices should be competent to:
help women to consider and compare the risks and benefits of all methods relevant to their individual needs manage common side effects and problems.
1.1.6.2 Contraceptive service providers who do not provide LARC in their practice or service should have an agreed mechanism in place for referring women for LARC.
1.1.6.3 Healthcare professionals providing intrauterine or subdermal contraceptives should receive training to develop and maintain the relevant skills to provide these methods.
1.1.6.4 IUDs and the IUS should only be fitted by trained personnel with continuing experience of inserting at least one IUD or one IUS a month.
1.1.6.5 Contraceptive implants should be inserted and removed only by healthcare professionals trained in the procedure.
More information
You can also see this guideline in the NICE Pathway on long-acting reversible contraception.
To find out what NICE has said on topics related to this guideline, see our web page on contraception.
See also the guideline committee's discussion and the evidence reviews (in the full guideline), and information about how the guideline was developed, including details of the committee.
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The MHRA issued a Drug Safety Update in January 2016 highlighting that levonorgestrelreleasing intrauterine systems should always be prescribed by brand name because products have different indications, durations of use, and introducers. Long-acting reversible contraception (CG30)
Research recommendations Research recommendations
The scarcity of robust evidence to answer important clinical questions on the use of LARC methods by women in the UK posed great challenges to the developers of the original guideline (October, 2005) . In the majority of cases, the guideline recommendations were based on extrapolated evidence that is indirect or of poor methodological quality. In 2005, the Guideline Development Group made the following recommendations for research on the basis of its review of the evidence.
In making these recommendations for research, the guideline developers consider it important and relevant that the research should be specific to the UK population because there are cultural differences in the response to side effects and non-contraceptive effects of hormonal contraceptives. In addition, freedom to choose any contraceptive method and the provision of a free contraceptive health service in the UK can influence important outcomes such as continuation rates and patterns of method switching. 
Typical use of contraception
Patterns of LARC use
Most women will need to use contraception for more than 30 years. Patterns of contraceptive use vary with age, ethnicity, marital status, fertility intention, education and lifestyle. Large prospective cohort studies are needed to identify:
patterns of use (initiation, continuation and switching between methods) of LARC methods compared with non-LARC methods factors that influence the patterns of use of LARC.
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